Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel on Day 1 Followed by IP Paclitaxel on Day 8 Every 21 Days as Front-Line Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

NCT00814086 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.

NCT NCT00814086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00814086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel on Day 1 Followed by IP Paclitaxel on Day 8 Every 21 Days as Front-Line Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Lead sponsor
Gynecologic Oncology Group
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2009
Completion date
Not reported
Enrollment
23 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapeutic agent toxicity, endometrial adenocarcinoma, fallopian tube carcinoma, gastrointestinal complication, malignant ovarian mixed epithelial tumor, neurotoxicity syndrome, ovarian brenner tumor, ovarian clear cell cystadenocarcinoma, ovarian mucinous cystadenocarcinoma, ovarian serous cystadenocarcinoma, primary peritoneal carcinoma, stage ii ovarian cancer, stage iii ovarian cancer, stage iv ovarian cancer, undifferentiated ovarian carcinoma